TRIM17: A Potential Drug Target and Biomarker for Ring Finger Protein 16

Target Name: TRIM17

NCBI ID: G51127

TRIM17

TRIM17: A Potential Drug Target and Biomarker for Ring Finger Protein 16

Ring finger protein 16 (RFP16) is a protein that is expressed in human tissues and is involved in various cellular processes. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore TRIM17, aputhenylmethionine-conjugated RNA polymerase (RNA polymerase II) subunit that is encoded by the TRIM17 gene, and its potential as a drug target and biomarker.

TRIM17: A Putative Drug Target

TRIM17 is a non-coding RNA polymerase that is expressed in various tissues of the human body, including muscle, liver, and brain. It is a member of the RNA polymerase II family, which are involved in the regulation of gene expression and have been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Studies have suggested that TRIM17 may be a potential drug target for various diseases. For example, TRIM17 has been shown to be involved in the regulation of cellular processes that are associated with the development and progression of cancer. In addition, TRIM17 has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

TRIM17 as a Biomarker

TRIM17 has also been shown to be a potential biomarker for various diseases. For example, TRIM17 has been shown to be involved in the regulation of cellular processes that are associated with the development and progression of cancer, including the regulation of cell cycle progression and the regulation of apoptosis.

In addition, TRIM17 has been shown to be involved in the regulation of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. These findings suggest that TRIM17 may be a useful biomarker for the diagnosis and treatment of autoimmune disorders.

TRIM17: A Promising Future

In conclusion, TRIM17 is a non-coding RNA polymerase that is expressed in various tissues of the human body. It has been shown to be involved in various cellular processes that are associated with the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. These findings suggest that TRIM17 may be a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of TRIM17 in disease progression and to develop effective treatments.

Protein Name: Tripartite Motif Containing 17

Functions: E3 ubiquitin ligase that plays important roles in the regulation of neuronal apoptosis, selective autophagy or cell proliferation (PubMed:22023800, PubMed:19358823, PubMed:27562068). Stimulates the degradation of kinetochore ZW10 interacting protein ZWINT in a proteasome-dependent manner, leading to negative regulation of cell proliferation (PubMed:22023800). Inhibits autophagic degradation of diverse known targets while contributing to autophagy of midbodies. Autophagy-inhibitory activity involves MCL1, which TRIM17 assembles into complexes with the key autophagy regulator BECN1 (PubMed:27562068). Controls neuronal apoptosis by mediating ubiquitination and degradation of MCL1 to initiate neuronal death. In addition, regulates NFAT transcription factors NFATC3 and NFATC4 activities by preventing their nuclear localization, thus inhibiting their transcriptional activities. Decreases TRIM41-mediated degradation of ZSCAN2 thereby stimulating alpha-synuclein/SNCA transcription in neuronal cells (By similarity). Prevents the E3 ubiquitin-ligase activity of TRIM28 and its interaction with anti-apoptotic BCL2A1, blocking TRIM28 from ubiquitinating BCL2A1 (PubMed:19358823)

The "TRIM17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets